SYRACUSE UNIVERSITY

Novel Peptide Compounds Show Promise as Ozempic Alternatives with Reduced GI Side Effects

4 months ago

• Researchers have developed two new peptide compounds, GEP44 and KCEM1, that target weight loss with potentially fewer gastrointestinal side effects than current GLP-1 drugs. • These compounds partner with PYY receptors, aiming to trigger significant weight loss without the nausea and vomiting often associated with GLP-1 receptor targeting medications. • A company co-owned by Syracuse University and the University of Pennsylvania is working to commercialize the compounds, with human trials anticipated within the next year. • Experts emphasize the need for a multidisciplinary approach to weight loss, including lifestyle and nutritional interventions, to address high discontinuation rates across weight loss treatments.

Aura Biosciences' Bel-sar Shows Promise in Choroidal Melanoma and Bladder Cancer Trials

6 months ago

• Aura Biosciences reports positive Phase 2 data for bel-sar in early-stage choroidal melanoma, demonstrating 80% tumor control and 90% visual acuity preservation. • Phase 1 trial of bel-sar in NMIBC shows clinical complete response in low-grade disease and immune activation, suggesting potential as a novel immune-ablative treatment. • The Phase 3 CoMpass trial for choroidal melanoma has received EMA authorization to begin enrolling patients in Europe, expanding the trial's global reach. • With a strong cash position, Aura Biosciences expects to fund operations into the second half of 2026, supporting ongoing clinical development programs.